Human Papillomavirus Immunity in Oropharyngeal Cancer: Time to Change the Game?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29133574.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2991.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For the first time, human papillomavirus (HPV)-specific immunity has been linked directly to the beneficial prognosis of oropharyngeal squamous cell carcinoma (OPSCC). Those patients lacking HPV immunity fare much worse. These results harbor crucial implications for future management of HPV-driven OPSCC as well as for its definition. <i>Clin Cancer Res; 24(3); 505-7. ©2017 AACR</i><i>See related article by Welters et al., p. 634</i>.
Medical subject headings
- Carcinoma, Squamous Cell
- Oropharyngeal Neoplasms
- Papillomaviridae
- Papillomavirus Infections